- Home
- WWR vs MDXH Comparison
WWR vs MDXH Comparison
Compare WWR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WWR | MDXH |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | United States | Belgium |
| Employees | 20 | N/A |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 68.7M |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WWR | MDXH |
|---|---|---|
| Price | $0.56 | $0.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.92 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 862.8K | 227.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $0.40 |
| 52 Week High | $3.75 | $5.33 |
Technical Indicators
Market Signals| Indicator | WWR | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 40.18 |
| Support Level | $0.54 | $0.51 |
| Resistance Level | $0.57 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 47.18 | 2.52 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.